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Abstract
Background: We assessed the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1)
antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC).
Methods: In this phase 1b expansion cohort, patients with mACC and prior platinum-based therapy received
avelumab at 10 mg/kg intravenously every 2 weeks. Continuation of mitotane was permitted; however,
mitotane levels during the study were not recorded. Tumor response was assessed by Response Evaluation
Criteria In Solid Tumors v1.1.
Results: Fifty patients received avelumab and were followed for a median of 16.5 months. Prior treatment
included ≥2 lines in 74.0%; mitotane was continued in 50.0%. The objective response rate (ORR) was 6.0%
(95% CI, 1.3% to 16.5%; partial response in 3 patients). Twenty-one patients (42.0%) had stable disease as best
response (disease control rate, 48.0%). Median progression-free survival was 2.6 months (95% CI, 1.4 to 4.0),
median overall survival (OS) was 10.6 months (95% CI, 7.4 to 15.0), and the 1-year OS rate was 43.4% (95% CI,
27.9% to 57.9%). In evaluable patients with PD-L1+ (n = 12) or PD-L1− (n = 30) tumors (≥5% tumor cell cutoff),
ORR was 16.7% vs 3.3% (P = .192). Treatment-related adverse events (TRAEs) occurred in 82.0%; the most
common were nausea (20.0%), fatigue (18.0%), hypothyroidism (14.0%), and pyrexia (14.0%). Grade 3 TRAEs
occurred in 16.0%; no grade 4 to 5 TRAEs occurred. Twelve patients (24.0%) had an immune-related TRAE of
any grade, which were grade 3 in 2 patients (4.0%): adrenal insufficiency (n = 1), and pneumonitis (n = 1).
Conclusions: Avelumab showed clinical activity and a manageable safety profile in patients with platinum-
treated mACC.
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Adrenocortical carcinoma (ACC) is a rare endocrine tumor
with an incidence of approximately 0.7 cases/1 million
population per year [1]. Genomic studies indicate that mu-
tations in defined driver genes, including zinc and ring fin-
ger 3 (ZNRF3), telomerase reverse transcriptase (TERT),
protein kinase cAMP-dependent type I regulatory subunit
alpha (PRKAR1A), ribosomal protein L22 (RPL22), telo-
meric repeat binding factor 2 (TERF2), cyclin E1 (CCNE1),
and neurofibromin 1 (NF1), may have a major role in the
etiology of ACC [2], and that ACC has a moderate overall
mutation burden compared with other tumor types [3]. Pa-
tients with ACC have a poor prognosis, with an estimated
5-year survival rate for metastatic ACC (mACC) of < 20%
[4–6]. Therapeutic options for mACC are limited and in-
clude surgery; platinum agents, mitotane, streptozocin, and
other systemic therapies; and locoregional radiotherapy [7].
Although cytotoxic treatments are widely administered,
they are associated with limited efficacy and high toxicity,
and targeted agents have not shown clinically meaningful
activity in this disease [8]. Thus, there is an urgent need for
new treatment options.
Cancer cells can exploit the programmed death 1 (PD-1)/
programmed death ligand 1 (PD-L1) immune checkpoint
pathway to promote an immunosuppressive environment
and allow tumor growth. Specifically, PD-L1 expressed on
tumor cells binds to PD-1 expressed on activated T cells,
resulting in downregulation of antitumor immune re-
sponses [9, 10]. Monoclonal antibodies targeting the PD-1/
PD-L1 axis have shown clinical activity in multiple tumor
types [11]. PD-L1 is expressed in ACC tissues throughout
various stages of disease, providing a rationale for assessing
anti–PD-1/PD-L1 antibodies in mACC [12].
Avelumab is a human IgG1 monoclonal antibody with a
wild-type Fc region that was designed to specifically bind
and block PD-L1 [13]. Unlike other anti–PD-L1/PD-1 anti-
bodies in clinical practice, avelumab is unique in that pre-
clinical models show that it can induce antibody-dependent
cellular cytotoxicity of tumor cells [14, 15]. Thus, avelumab
may engage both the adaptive and innate immune systems.
Avelumab treatment has been associated with durable re-
sponses in several tumor types [16–18], and avelumab has
been approved in various countries for the treatment of pa-
tients with metastatic Merkel cell carcinoma and in the
United States and Canada for treatment of locally advanced
or metastatic urothelial carcinoma that progressed during
or after platinum-containing chemotherapy [19]. Here we
report results from a phase 1b cohort of patients with pre-
viously treated mACC who received avelumab.
Methods
Study design and treatment
JAVELIN Solid Tumor (ClinicalTrials.gov ID NCT01772004)
in an international, multicenter, phase 1, open-label
trial designed to investigate the clinical activity, safety,
and pharmacokinetics of avelumab in patients with
metastatic solid tumors, with expansion in selected
tumor types. Findings from the dose-escalation portion
of this study (phase 1a) were reported previously [13].
In this phase 1b dose-expansion cohort, eligible pa-
tients were aged ≥18 years and had an Eastern Co-
operative Oncology Group performance status (ECOG
PS) of ≤1; histologically or cytologically confirmed
mACC with ≥1 measurable lesion; ≥1 line of prior sys-
temic therapy for metastatic disease (including ≥1
platinum-based therapy); and relapsed, refractory, or
progressive disease following last line of treatment. Pa-
tients receiving mitotane were permitted to continue
treatment during the trial; however, details relating to
ongoing mitotane treatment was not systematically col-
lected and mitotane levels during the study were not
recorded. Patients were also required to have adequate
hematologic, hepatic, and renal function and availability
of a fresh or archival tumor specimen. Exclusion cri-
teria included prior treatment with a T cell-targeting
immune checkpoint inhibitor, other cancer diagnosis
within 5 years, rapidly progressive disease, CNS metas-
tases, known autoimmune disease, or ongoing steroid
treatment (except for patients with adrenal insuffi-
ciency, who could continue treatment at a physiological
replacement dose).
The trial was conducted in accordance with the ethics
principles of the Declaration of Helsinki and the Inter-
national Council for Harmonisation Guidelines on Good
Clinical Practice. The protocol was approved by the in-
stitutional review board or independent ethics commit-
tee of each center. All patients provided written
informed consent before enrollment.
Procedures
Avelumab (EMD Serono, Rockland, MA) 10 mg/kg was ad-
ministered intravenously over 60 mins every 2 weeks until
progression, unacceptable toxicity, or other protocol-based
criteria for withdrawal occurred. Dose modifications were
not permitted. Treatment was discontinued following: 1)
any grade 4 adverse event (AE) except for single laboratory
values out of the normal range that were unrelated to study
treatment, without clinical correlate, and resolved within
7 days with medical management; 2) any grade 3 AE except
for: (i) transient (≤6 h) influenza-like symptoms or pyrexia
controlled with medical management; (ii) fatigue, local
infusion-related reaction, headache, nausea, or emesis that
resolved to grade ≤ 1 within 24 h; (iii) single laboratory
values out of the normal range that were unrelated to study
treatment and without clinical correlate (excluding grade ≥ 3
increase in liver enzyme concentrations) that resolved to
grade ≤ 1 within 7 days; (iv) tumor flare phenomena (local
pain, irritation, or localized rash at a tumor site); (v) grade ≥




















3 amylase or lipase abnormality not associated with symp-
toms or clinical manifestations of pancreatitis; or 3) increase
in Eastern Cooperative Oncology Group performance status
to ≥3 not resolved to ≤2 by Day 14 of the following cycle.
Grade 2 AEs were managed by dose delays; events that did
not resolve to grade ≤ 1 by the end of the next treatment
cycle or recurred led to permanent discontinuation of avelu-
mab (except for hormone insufficiencies that could be man-
aged by replacement therapy). A premedication regimen of
diphenhydramine and acetaminophen was administered 30
to 60 min before all avelumab infusions.
Safety was assessed at each biweekly trial visit and in-
cluded assessment of AEs, physical examination, and
clinical laboratory tests. AEs and laboratory abnormal-
ities were graded according to the National Cancer Insti-
tute Common Terminology Criteria for Adverse Events
v4.0. A serious AE (SAE) was defined as any untoward
event that was life-threatening, required hospitalization,
resulted in disability, was a congenital anomaly, or re-
sulted in death. Immune-related AEs were identified
using a prespecified list of Medical Dictionary for Regu-
latory Activities terms.
Clinical activity was assessed by investigators using Re-
sponse Evaluation Criteria In Solid Tumors (RECIST) v1.1
[20] and modified immune-related response criteria [21].
Radiographic tumor assessments were completed at base-
line and then every 6 weeks. For patients who had a partial
response (PR) or complete response (CR), a confirmatory
computed tomography or magnetic resonance imaging
scan was completed ≥28 days later, preferably at the
scheduled 6-week interval. PD-L1 expression was assessed
using a proprietary immunohistochemistry assay (Dako
PD-L1 IHC 73–10; Dako, Carpinteria, CA) [18].
Outcomes
Primary endpoints for the whole JAVELIN Solid Tumor
trial are the occurrence of dose-limiting toxicities during
the first 3 weeks of treatment in the phase 1a
dose-escalation part (reported previously) [13] and con-
firmed best overall response adjudicated by an independent
review committee in specified expansion cohorts. Prespeci-
fied endpoints assessed in this cohort included best overall
response per investigator assessment (defined as best re-
sponse per RECIST v1.1 obtained among all tumor assess-
ments after the start of treatment with avelumab until
documented disease progression), immune-related best
overall response, duration of response (defined as the time
from first documented PR or CR until progressive disease
or death, whichever occurred first), progression-free sur-
vival (PFS), overall survival (OS), evaluation of PD-L1 ex-
pression, and safety (including incidence and severity of
AEs). Change in the sum of target lesion diameters from
baseline over time was evaluated in patients with baseline
tumor assessments and ≥ 1 postbaseline assessment.
Statistical analysis
Enrollment of 50 patients was planned for this cohort; this
sample size was selected to provide point estimates and
95% Clopper-Pearson CIs for an objective response rate
(ORR; proportion of patients with a PR or CR) of 10% (95%
CI, 3.3% to 21.8%) in the case of 5 responders, and 20%
(95% CI, 10.0% to 33.7%) in the case of 10 responders.
Safety and clinical activity were analyzed in all patients who
received ≥1 dose of avelumab. Time-to-event endpoints
were estimated with the Kaplan-Meier method, and CIs for
the median were calculated using the Brookmeyer-Crowley
method. P values for association between categorical vari-
ables were determined using the Fisher exact test.
Results
Between September 9, 2014, and the data cutoff date of
December 31, 2016, 50 patients were enrolled in 6 coun-
tries. Median age was 50 years (range, 21 to 71 years)
(Table 1). Patients were heavily pretreated; the median
number of prior lines of systemic therapy was 2 (range,
1 to 6), and 37 patients (74.0%) had received ≥2 prior
lines. Date of disease progression before enrollment was
documented in 49 patients, and median time since last
disease progression was 0.92 months (range, 0.33 to
8.61 months). Twenty-five patients (50%) continued to
receive concurrent mitotane. Median duration of avelu-
mab treatment was 3.4 months (range, 0.5 to
24.8 months), and median follow-up was 16.5 months
(range, 11.7 to 27.6 months). Patients received a median
7 doses of avelumab (range, 1 to 52). At data cutoff, 5
patients (10.0%) remained on treatment. Reasons for
treatment discontinuation were disease progression (n =
32 [64.0%]), AE (n = 5 [10.0%]), death (n = 3 [6.0%]),
withdrawal of consent (n = 2 [4.0%]), protocol noncom-
pliance (n = 1 [2.0%]), and other (n = 2 [4.0%]).
Of 50 patients enrolled, 3 had confirmed PRs, and the
ORR was 6.0% (95% CI, 1.3% to 16.5%) (Table 2). Of the
3 responding patients, 2 were receiving concomitant
mitotane (both had prior progression while receiving
mitotane), and 2 had PD-L1+ tumors (based on 1% or
5% expression cutoffs). In patients who had received 1
(n = 13), 2 (n = 18), or ≥ 3 (n = 19) prior lines of systemic
therapy since diagnosis, ORR was 15.4%, 5.6%, and 0%,
respectively. Response was ongoing in 1 patient, who
had a duration of response of 19.4 months at data cutoff
(Fig. 1); this was a man aged 63 years with a PD-L1−
tumor who had received prior treatment with cisplatin,
etoposide, and mitotane and had target lesions in the
liver and lymph node (Additional file 1: Figure S1). The
patient received avelumab with concurrent mitotane,
had a PR documented at the second assessment (week
13), and remained on treatment without progression
throughout 22.0 months of follow-up. Twenty-one pa-
tients had a best response of stable disease, resulting in a




















disease control rate of 48.0%, which was the same in pa-
tients with or without concomitant mitotane. Using
immune-related response criteria, ORR was 6.0% (95%
CI, 1.3% to 16.5%), and the disease control rate was
58.0% (Additional file 1: Table S1). Of 48 patients evalu-
able for change in tumor size, 16 (33.3%) had a reduc-
tion of any level vs baseline, including a reduction of
≥30% in 4 patients (8.0%) (Fig. 2a). One patient had an
initial assessment showing progressive disease (~ 100%
increase vs baseline and new lesion at week 7) but later
assessments showed a decrease vs baseline (nadir − 74%;
Fig. 2b).
Median PFS was 2.6 months (95% CI, 1.4 to 4.0), and
PFS rates at 6 months and 1 year were 20.9% (95% CI,
10.6% to 33.5%) and 8.7% (95% CI, 2.6% to 19.6%), re-
spectively (Fig. 3a). Using immune-related criteria, median
PFS was 3.8 months (95% CI, 2.4 to 5.5). Median OS was
10.6 months (95% CI, 7.4 to 15.0), and the 1-year OS rate
was 43.4% (95% CI, 27.9% to 57.9%) (Fig. 3b).
PD-L1 expression was evaluable in tumor samples
from 42 patients (84%). In patients with PD-L1+ (n = 12)
or PD-L1– (n = 30) tumors based on a 5% PD-L1 expres-
sion cutoff, ORR (95% CI) was 16.7% (2.1% to 48.4%) vs
3.3% (0.1% to 17.2%) (P = .192), median PFS was 5.5 (1.3
to 8.2) vs 1.7 (1.4 to 4.0) months (HR, 0.66 [95% CI, 0.32
to 1.39]), and median OS was 14.4 (7.4 to 14.4) vs 10.6
(7.3 to not evaluable) months (HR, 0.91 [95% CI, 0.33 to
2.49]) (Fig. 3c and Fig. 3d). Findings were similar based
on analyses of PD-L1 expression using a 1% cutoff (Add-
itional file 1: Table S2 and Figure S2). Analyses of higher
tumor cell PD-L1 cutoffs and PD-L1 expression on
tumor-infiltrating immune cells were not informative be-
cause few patients had PD-L1+ tumors (0 to 5 patients).
All 50 patients (100.0%) had an AE of any grade; 41 pa-
tients (82.0%) had a treatment-related AE (TRAE) (Table 3).
The most common TRAEs of any grade were nausea (n =
10; 20.0%), fatigue (n= 9; 18.0%), hypothyroidism (n = 7;
14.0%), and pyrexia (n= 7; 14.0%). Five patients (10%) had
an infusion-related reaction; all were grade 1 or 2. Eight pa-
tients (16.0%) had a grade 3 TRAE and no patient had a
grade 4 or 5 TRAE. Of patients with or without concomitant
Table 1 Patient Demographics and Baseline Characteristics
Characteristics (N = 50)
Age, median (range), years 50.0 (21–71)
< 65 years, n (%) 46 (92.0)








ECOG PS, n (%)
0 19 (38.0)
1 31 (62.0)
Median time since first diagnosis (range), years 1.6 (0.2–15.1)
Median time since last disease progression (range),
months
0.92 (0.33–8.61)




≥ 4 9 (18.0)
Receiving concomitant mitotane, n (%) 25 (50.0)
PD-L1 expression on tumor cells (≥1% cutoff), n (%)
Negative 27 (54.0)
Positive 15 (30.0)
Not evaluable 8 (16.0)
PD-L1 expression on tumor cells (≥5% cutoff), n (%)
Negative 30 (60.0)
Positive 12 (24.0)
Not evaluable 8 (16.0)
Table 2 Confirmed Best Overall Response Based on RECIST v1.1
Response With Mitotane (n = 25) Without Mitotane (n = 25) Overall (N = 50)
Confirmed best overall response, n (%)
Complete response 0 0 0
Partial response 2 (8.0) 1 (4.0) 3 (6.0)
Stable disease 10 (40.0) 11 (44.0) 21 (42.0)
Progressive disease 10 (40.0) 13 (52.0) 23 (46.0)
Not evaluable 3 (6.0) 0 3 (6.0)
ORR (95% CI), % 8.0 (1.0–26.0) 4.0 (0.1–20.4) 6.0 (1.3–16.5)
Disease control rate, % 48.0 48.0 48.0
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Fig. 1 Time to and duration of response or stable disease (n = 24). Bars represent individual patients with partial response or stable disease. At

















































PD-L1+ (n = 12)
PD-L1– (n = 29)
Not evaluable for PD-L1 expression (n = 7)
Partial response (n = 3)
Stable disease (n = 21)
Progressive disease (n = 23)
Not evaluable (n = 1)










































Time since treatment initiation (months)
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Fig. 2 a Best change and b change over time from baseline in sum of target lesion diameters in evaluable patients (n = 48). In a bars for
individual patients are color-coded according to tumor PD-L1 status based on a 5% PD-L1 expression cutoff in tumor cells. In b lines for
individual patients are color-coded based on confirmed best overall response




















mitotane treatment during avelumab treatment (n = 25 in
each group), 6 (24.0%) vs 2 (8.0%) patients had a grade 3
TRAE, respectively. Increase in alanine aminotransferase
level (n = 2) was the only grade 3 TRAE that occurred in
more than 1 patient; both patients received concomitant
mitotane. Treatment-related grade 3 elevations in liver en-
zyme levels occurred only in patients who received con-
comitant mitotane. Twelve patients (24.0%) had an
immune-related TRAE of any grade; those occurring in ≥1
patient were hypothyroidism (n = 7), adrenal insufficiency
(n = 3), and pneumonitis (n = 2). Two patients (4.0%) had a
grade 3 immune-related TRAE: adrenal insufficiency (n =
1) and pneumonitis (n = 1). Thirty-two patients (64.0%) had
an SAE; in 4 patients (8.0%), the SAE was treatment related:
pneumonitis (n = 1), adrenal insufficiency and transaminitis
(n = 1), thyroiditis (n = 1), and pyrexia (n = 1). Six patients
(12.0%) had AEs that led to death, but none were treatment
related: disease progression (n = 4), failure to thrive (n = 1),
and respiratory failure (n = 1).
Discussion
In this single-arm phase 1b study, which to our know-
ledge is the largest prospective trial of a checkpoint in-
hibitor in mACC, avelumab showed antitumor activity
with an acceptable safety profile in a platinum-treated
population. Three patients (6.0%) had an objective re-
sponse, including patients with PD-L1+ and PD-L1−
tumors, and all of whom had received only 1 (n = 2) or 2
(n = 1) prior lines of treatment. This suggests that the
activity of avelumab might be greatest in patients with
limited pretreatment, although the small patient num-
bers in this study prevent any definitive conclusion. Rea-
sons for improved response in patients with less
pretreatment may include a smaller tumor burden, de-
creased proportion of treatment-resistant cells within
the tumor, and reduced immunosuppression associated
with multiple prior lines of chemotherapy. Although the
ORR and median PFS were modest in this heavily pre-
treated population, the disease control rate was 48.0%,
median OS was 10.6 months, and the 1-year OS rate
was 43.0%. No association was seen between concomi-
tant mitotane treatment and clinical activity of avelu-
mab, although the absence of detailed patient data
relating to ongoing mitotane treatment, including drug
levels, is a limitation of the study.
Apart from the current study, other data reported in
ACC with anti–PD-L1/PD-1 agents are preliminary find-
ings from phase 2 studies of nivolumab and pembrolizu-
mab in patients with previously treated advanced ACC.
Of 7 patients who received nivolumab, 5 had a best re-
sponse of disease progression and 2 were awaiting evalu-
ation [22]. Of 11 patients who received pembrolizumab,
2 had a PR, 1 achieved stable disease, and the 6-month
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Fig. 3 a PFS and b OS in the overall population (N = 50), and c PFS and d OS based on PD-L1 expression on tumor cells (5% cutoff) in evaluable
patients (n = 42). NE, not evaluable




















of avelumab in patients with various advanced malignan-
cies, a PR occurred in a patient with ACC [13].
The manageable safety profile of avelumab seen in pa-
tients with mACC was consistent with experience in
other tumor types [16–18]. Patients receiving concomi-
tant mitotane had a higher rate of grade 3 TRAEs than
those not receiving mitotane (24.0% vs 8.0%), particu-
larly liver enzyme elevations. This reflects the known
toxicity profile of mitotane, which includes hepatic,
gastrointestinal, neurological, and hematologic AEs [24].
However, our study showed that the tolerability of avelu-
mab and mitotane in combination is acceptable.
Current treatment options for patients with mACC are
highly limited. In the first-line setting, response rates with
mitotane monotherapy are estimated to be approximately
10% to 30%, although data from prospective trials are lack-
ing [7]. In a randomized phase 3 study of mitotane com-
bined with either etoposide, doxorubicin, and cisplatin or
streptozocin in patients with unresectable ACC without
prior treatment (except mitotane), the ORR was 23.2% vs
9.2% (P < .001), the disease-control rate was 58.3% vs 31.4%
(P < .001), median PFS was 5.0 vs 2.1 months (P < .001),
median OS was 14.8 vs 12.0 months (P = .07), and serious
AEs occurred in 58.1% vs 41.6% of patients [25]. In a phase
2 trial of gemcitabine plus metronomic fluoropyrimidine as
second-/third-line treatment in patients with advanced
ACC who were receiving ongoing mitotane treatment (n =
28), the ORR was 7.1%, disease control rate was 46.4%, me-
dian time to progression was 5.3 months, and median OS
was 9.8 months; grade 3/4 AEs were leukopenia (21.4%),
thrombocytopenia (3.5%), and mucositis (3.5%) [26]. Thus,
the results from our study indicate that avelumab has com-
parable clinical activity and may be better tolerated than
existing treatment options for this hard-to-treat cancer. A
randomized phase 2 study in non-small-cell lung cancer
has shown that combining an anti–PD-1 antibody with
platinum-based chemotherapy increased the ORR and pro-
longed PFS vs chemotherapy alone [27]. This suggests that
studies in ACC of avelumab in combination with chemo-
therapy or as maintenance therapy after first-line induction
chemotherapy are warranted.
Targeted molecular therapies have been explored in pa-
tients with previously treated advanced ACC, but efficacy
has been poor or nonexistent. In a phase 3 trial of linsiti-
nib (insulin-like growth factor receptor 1 and insulin re-
ceptor inhibitor) vs placebo in 139 patients with
previously treated ACC, of whom 55% had received prior
cisplatin, ORR was 3.3% vs 0%, disease control rate was
32.2% vs 34.7%, median PFS was 44 vs 46 days (P = .30),
and median OS was 323 vs 356 days (P = .77) [28].
Table 3 TRAEs by Concomitant Mitotane Treatment (any grade in ≥10% of patients in either group or grade 3 in any patient)
TRAE With Mitotane (n = 25) Without Mitotane (n = 25)
Any Grade Grade 3 Any Grade Grade 3
Any TRAE, n (%) 21 (84.0) 6 (24.0) 20 (80.0) 2 (8.0)
Nausea 7 (28.0) 0 3 (12.0) 0
Fatigue 5 (20.0) 0 4 (16.0) 0
Pyrexia 5 (20.0) 0 2 (8.0) 0
ALT increased 4 (16.0) 2 (8.0) 1 (4.0) 0
AST increased 4 (16.0) 1 (4.0) 1 (4.0) 0
Asthenia 3 (12.0) 0 1 (4.0) 0
Back pain 3 (12.0) 0 0 0
Chills 3 (12.0) 0 2 (8.0) 0
Diarrhea 3 (12.0) 0 2 (8.0) 0
Hypothyroidism 3 (12.0) 0 4 (16.0) 0
Adrenal insufficiency 2 (8.0) 1 (4.0) 1 (4.0) 0
GGT increase 2 (8.0) 1 (4.0) 0 0
Vomiting 2 (8.0) 0 4 (16.0) 0
Anemia 1 (4.0) 1 (4.0) 2 (8.0) 0
Hypophosphatemia 1 (4.0) 0 2 (8.0) 1 (4.0)
Infusion-related reaction 1 (4.0) 0 4 (16.0) 0
Lymphopenia 1 (4.0) 1 (4.0) 0 0
Transaminases increased 1 (4.0) 1 (4.0) 0 0
Pneumonitis 0 0 2 (8.0) 1 (4.0)
Abbreviations: ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT γ-glutamyltransferase




















Treatment with erlotinib (tyrosine kinase inhibitor [TKI]
of epidermal growth factor receptor) plus gemcitabine in
10 patients resulted in tumor-size reduction in 1 patient,
whereas 8 patients had progressive disease at first evalu-
ation [29]. In other studies, no patient treated with combi-
nations of bevacizumab (anti-VEGF antibody) plus
capecitabine [30] or sorafenib (multi-TKI) plus paclitaxel
[31] had an objective response or stable disease. In a study
of axitinib (VEGF receptor inhibitor), none of 13 patients
had an objective response, 4 patients showed decreased
tumor growth, and median PFS was 5.5 months [32].
Among 35 evaluable patients who received sunitinib (mul-
ti-TKI), 14.2% had stable disease as best response and me-
dian PFS was 2.8 months [33]. In a study assessing
cixutumumab (anti-insulin growth factor 1 receptor anti-
body) plus temsirolimus (mTOR inhibitor), 11 of 26 pa-
tients (42.3%) had a best response of stable disease [34].
Thus, the activity of immunotherapy may be more prom-
ising than seen to date in studies of targeted therapies.
Conclusions
In patients with mACC previously treated with
chemotherapy, avelumab had moderate clinical activ-
ity either as monotherapy or with concurrent mito-
tane (50% of patients), particularly in those with
limited pretreatment or PD-L1+ tumors, and with an
acceptable safety profile. These findings provide a ra-
tionale for studies of avelumab-based combination
treatment in patients with advanced ACC.
Additional file
Additional file 1: Table S1. Confirmed best objective response based
on modified immune-related response criteria. Table S2. Antitumor activity
based on PD-L1 expression on tumor cells (1% and 5% cutoffs) in evaluable
patients (n = 42). Figure S1. Computed tomography scans of a patient with
adrenocortical carcinoma who experienced a long-term tumor response
with avelumab treatment. The patient had a partial response documented
at the second assessment (week 13) and remained on treatment without
progression until last follow-up. Figure S2. (A) Progression-free survival
(PFS) and (B) overall survival (OS) based on programmed death ligand 1
(PD-L1) expression on tumor cells (1% cutoff) in evaluable patients (n = 42).
ACC, adrenocortical carcinoma; NE, nonevaluable. (DOCX 498 kb)
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ACC: Adrenocortical carcinoma; AE: Adverse event; ALT: Alanine
aminotransferase; AST: Asparate aminotransferase; CCNE1: Cyclin E1;
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